| Date | Title | Description |
| 10.01.2022 | IsoPlexis Reports Preliminary Full Year 2021 Revenue, Releases Industry-First Superhuman Cell Library | BRANFORD, Conn., Jan. 09, 2022 (GLOBE NEWSWIRE) -- IsoPlexis (NASDAQ: ISO), the Superhuman Cell Company, today announced its preliminary unaudited revenue for the full year 2021. Total revenue for 2021 is expected to be in the range of $17.... |
| 10.01.2022 | IsoPlexis : Reports Preliminary Full Year 2021 Revenue, Releases Industry-First Superhuman Cell Library - Form 8-K | IsoPlexis Reports Preliminary Full Year 2021 Revenue, Releases Industry-First Superhuman Cell Library
Superhero cells are key to the efficacy, potency, and durability of therapies across the human health spectrum
BRANFORD, Conn., Jan. 9, 20... |
| 30.11.2021 | IsoPlexis Appoints Key Financial and Legal Hires from Leading Tools and Omics Companies | BRANFORD, Conn., Nov. 30, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ: ISO), the leader in functional single-cell proteomics, today announced the appointment of Richard Rew as Senior VP, General Counsel and Secretary; Raj Khakhar as VP of Financ... |
| 10.11.2021 | IsoPlexis Reports Third Quarter 2021 Financial Results | BRANFORD, Conn., Nov. 10, 2021 /PRNewswire/ -- IsoPlexis Corporation (Nasdaq: ISO), the leader in functional single-cell proteomics, today reported financial results for the quarter ended September 30, 2021.
Recent Highlights
Revenue of $4.... |
| 12.10.2021 | IsoPlexis : Announces Closing of Public Offering | BRANFORD, Conn., Oct. 12, 2021 /PRNewswire/ -- IsoPlexis Corporation ("IsoPlexis"), a leader in functional single-cell proteomics, today announced the closing of its initial public offering of 8,333,000 shares of common stock at a... |
| 08.10.2021 | IsoPlexis : Announces Pricing of Initial Public Offering | BRANFORD, Conn., Oct. 7, 2021 /PRNewswire/ -- IsoPlexis Corporation ("IsoPlexis"), a leader in functional single-cell proteomics, today announced the pricing of its initial public offering of 8,333,000 shares of common stock at a ... |
| 08.10.2021 | IsoPlexis, a company uncovering a ‘new layer’ of cell data, aims for $125M in market debut | Shares of IsoPlexis, a company creating tools to zoom in on the flurry of protein activity surrounding a single cell, began trading on Friday. The company aims to raise about $125 million with the IPO, which will be used to build the commer... |
| 24.06.2021 | Lyndra banks $60.5M to bring ultralong-acting pill into pivotal schizophrenia trial
Are Real-time Gene Therapy Results Possible? | As Lyndra Therapeutics mulls partnerships to build out its pipeline of central nervous system disorder treatments, it’s raised $60.5 million to move its lead program, a once-weekly pill for schizophrenia, into a pivotal trial.
RELATED: Gile... |
| 24.06.2021 | Belldegrun's VC firm nabs a major $825M funding well for next-gen biotechs
Are Real-time Gene Therapy Results Possible? | After an illustrious career in biotech, including navigating Kite Pharma and then Allogene to become major players in the cell therapy space, Arie Belldegrun, M.D., and his new venture firm are looking to make a series of bets on the next b... |
| 23.06.2021 | Abata hopes to find ‘perfect fit’ with MS cell therapy after $95M series A
Fierce Pharma Webinar | EMBARGOED until Wednesday, June 23 at 7 a.m. ET
Third Rock is joined by ElevateBio, Lightspeed Venture Partners, Invus, Samsara BioCapital and the JDRF T1D Fund in the financing.
Tregs are the “ideal therapy for autoimmune disease” because ... |
| 23.06.2021 | Strand snags $52M to develop next-gen mRNA meds for cancer
Fierce Pharma Webinar | For many, mRNA-based medicines are synonymous with COVID-19 vaccines, but vaccination is just the tip of the iceberg for the technology. Strand Therapeutics is one of the companies looking below the surface, and it’s raised $52 million to g... |
| 23.06.2021 | Portable dialysis machine maker Quanta lands $245M to boost U.S. reach
Are Real-time Gene Therapy Results Possible? | After starting off 2021 with an FDA clearance for its portable dialysis machine, Quanta Dialysis Technologies has now raised a massive $245 million venture capital round to help roll out its next-generation device to both acute and chronic ... |
| 22.06.2021 | TRexBio has Jurassic day picking up ex-Lilly VP as CEO, snagging Big Pharma funding
Are Real-time Gene Therapy Results Possible? | The next installment of the "Jurassic Park" franchise doesn't hit theaters for another 12 months, so, TRexBio had to make a Jurassic (read: drastic) splash of its own.
Joining the C-suite are Johnston Erwin and Ovid Trifan, M.D., ... |
| 22.06.2021 | Blackstone, Cellex and Intellia form $250M CAR-T startup
Are Real-time Gene Therapy Results Possible? | Blackstone Life Sciences, Cellex Cell Professionals and Intellia Therapeutics have teamed to create a CAR-T therapy startup. The biotech begins life with $250 million from Blackstone, universal CAR-T platforms from Cellex and CRISPR/Cas9 ge... |
| 22.06.2021 | Insilico Medicine scores $255M venture round to move AI-designed drugs into human clinical trials
Fierce Pharma Webinar | The advent of artificial intelligence holds the promise to reset the industry’s expectations of how long it should take to develop a new drug from scratch. And with serious new investments, Insilico Medicine is looking to make it an everyda... |
| 21.06.2021 | Cleerly launches with $43M to tackle heart attacks with AI-powered imaging
Fierce Pharma Webinar | Using artificial intelligence-powered imaging tech developed at Weill Cornell Medicine and New York-Presbyterian Hospital, Cleerly has launched to help provide a digital-first approach to preventing heart attacks.
“Advanced imaging has been... |
| 26.05.2021 | Slone Partners Places Siddhartha Kadia on Board of Directors at IsoPlexis | “Siddhartha Kadia is a highly accomplished and esteemed scientist and biotechnology business leader with a stellar track record of success,” said Slone Partners CEO Leslie Loveless.
SOUTH RIDING, Va. (PRWEB) May 26, 2021
Slone Partners, a n... |
| 11.01.2021 | IsoPlexis secures $135M to boost its single-cell protein analysis tech
W h i t e p a p e r
Weighing the Costs: | As single-cell analysis technologies continue their rapid development—promising a cell’s-eye view of protein interactions and signaling—IsoPlexis hopes to establish itself as a provider of next-generation biology tools with $135 million in ... |
| 07.01.2021 | IsoPlexis Announces $135M Series D Round |
BRANFORD, CT, IsoPlexis, the leader in single-cell functional proteomics, announced a $135 million Series D financing comprised of $85 million in equity securities and a $50 million credit facility.
>> Click here for more funding d... |
| 07.01.2021 | IsoPlexis Announces $135 Million Series D Led by Perceptive Advisors | IsoPlexis, the leader in single-cell functional proteomics, today announced a $135 million Series D financing comprised of $85 million in equity securities and a $50 million credit facility. The round was led by Perceptive Advisors with par... |
| 07.01.2021 | IsoPlexis Announces $135 Million Financing Led by Perceptive Advisors | |
| 11.11.2020 | IsoPlexis Launches Personalized Lab System, the IsoSpark, to Continue Scaling to Many Labs Worldwide | |
| 09.01.2020 | IsoPlexis Raises Additional $20M in Series C Financing | IsoPlexis, a Branford, Conn.-based developer of single-cell functional proteomics, raised an additional $20m in its Series C financing, bringing the entire Series C round to $45m.
The round was led by Northpond Ventures with participation f... |
| 09.01.2020 | IsoPlexis Closes Additional $20 Million Financing | IsoPlexis, the leader in single-cell functional proteomics, has announced today that it has raised an additional $20 million in its Series C financing, bringing the entire Series C round to $45 million. The funding will continue to drive th... |
| 15.05.2019 | Term Sheet — Wednesday, May 15 | THE UNICORN PARADE
Deals, deals, deals. Here are three to have on your radar today:
Paid Content Securing the enterprise without boundaries From ExtraHop
The online grocery category is red hot right now. Digital food retailing is expected t... |
| 14.05.2019 | IsoPlexis Completes $25 Million Series C Financing | IsoPlexis, a company focused on advancing single-cell biomarkers to address critical challenges in oncology & beyond, today announced that it had raised $25 million in Series C funding. The round was led by Northpond Ventures and includ... |
| 14.05.2019 | IsoPlexis Receives $25M Series C Funding |
BRANFORD, CT, IsoPlexis today announced that it had raised $25 million in Series C funding.
>> Click here for more funding data on IsoPlexis
>> To export IsoPlexis funding data to PDF and Excel, click here
IsoPlexis, a co... |
| 14.05.2019 | Daily funding roundup - May 14th, 2019 | Storr raised $3M; Skylark closed $4M; Webscale landed $14M; Innowatts secured $18.2M
Storr: Storr enables anyone to open a store from their phone. On Storr, people make money selling products instead of retailers like Amazon. Storr has rais... |
| 14.05.2019 | IsoPlexis Closes $25M Series C Financing | IsoPlexis, a Branford, Conn.-based company focused on advancing single-cell biomarkers to address critical challenges in oncology & beyond, raised $25m in Series C funding.
The round was led by Northpond Ventures with participation from... |
| 25.09.2017 | IsoPlexis Raises $13.5M in Series B |
BRANFORD, CT, Life science company at the forefront of single-cell analytics technology and the immune-based cancer treatment revolution, has raised $13.5M in its Series B financing round.
>> Click here for more funding data on Iso... |
| 25.09.2017 | Term Sheet — Monday, September 25 | ELON MUSK STRIKES AGAIN
Good morning, Term Sheet readers.
Paid Content Securing the enterprise without boundaries From ExtraHop
UBER’S SOFT SIDE: Across the ocean, Uber began its morning with an apology to British regulators after the ride-... |
| 25.09.2017 | IsoPlexis Raises $13.5M in Series B Financing | IsoPlexis Corporation, a Branford, Conn-based life science company, raised $13.5m in its Series B financing round.
The round was led by Spring Mountain Capital, with participation by Connecticut Innovations, North Sound Ventures, and Ironwo... |
| 25.09.2017 | IsoPlexis Raises $13.5 Million Series B | IsoPlexis Corporation (IsoPlexis), a privately held life science company at the forefront of single-cell analytics technology and the immune-based cancer treatment revolution, has announced today that it raised $13.5 million in its Series B... |
| 29.05.2015 | Yale spinout Isoplexis raises $2.4M for “cellular fingerprinting” tech that analyzes immune response | It has a patent-pending “biochip” technology that analyzes and “fingerprints” single cells, studying their excretion of a number of proteins like cytokines, chemokines and growth factors. This, in turn, helps construct “a highly accurate pi... |
| 12.08.2014 | IsoPlexis Raises $300K from Connecticut Innovations | IsoPlexis, a Branford, Conn.-based life science research tools company, raised $300k from Connecticut Innovations (CI).
The company intends to use the funds to conduct engineering and software updates, finalize a beta version of its product... |
| 11.08.2014 | IsoPlexis Raises $300K |
BRANFORD, CT, IsoPlexis, a life science research tools company received a $300,000 investment.
>> Click here for more funding data on IsoPlexis
>> To export IsoPlexis funding data to PDF and Excel, click here
Connecticut ... |
| 01.08.2014 | Yale student entrepreneur spinout IsoPlexis raising $1.7 million for “cellular fingerprinting” | It has a patent-pending “biochip” technology that analyzes and “fingerprints” single cells, studying their excretion of a number of proteins like cytokines, chemokines and growth factors. This, in turn, helps construct “a highly accurate pi... |
| - | Yale spinout Isoplexis raises $2.4M for “cellular fingerprinting” tech that analyzes immune response | More funding on the books for Yale spinout Isoplexis: It just raised $2.4 million of a potential $3.8 million round, according to a regulatory filing.
The startup’s developing an assay that helps researchers better understand immune respons... |
| - | Yale student entrepreneur spinout IsoPlexis raising $1.7 million for “cellular fingerprinting” | IsoPlexis, a Yale spinout developing an immunologic assay that helps researchers understand how therapies impact individual patients on a cellular level, seems to have raised a nice chunk of startup capital.
The company, formed last year by... |
